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ABSTRACT 
With the recent advances of nanotechnology, dendrimers are emerging as a highly attractive class of drug delivery vectors for cancer therapy. 
Dendrimers are multifunctional smart Nanocarriers to deliver one or more therapeutic agent safely and selectively to cancer cells. The high level of 
control over the synthesis of dendritic architecture makes dendrimers a nearly perfect (spherical) nanocarrier for site-specific drug delivery. The 
presence of functional groups in the dendrimers exterior also permits the addition of other moieties that can actively target certain diseases which 
are now widely used as tumor targeting strategies. Drug encapsulation, solubilization and passive targeting also equally contribute to the 
therapeutic use of dendrimers. Dendrimers are ideal carrier vehicles on cytotoxicity, blood plasma retention time, biodistribution and tumor 
uptake. In this review we highlight the advantages of dendrimers over conventional chemotherapy, toxicity and its management, following anti-
cancer drugs delivered by using dendrimers and recent advances in drug delivery by various types of dendrimers as well as its diagnostic 
applications. 
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Cancer is one of the world’s most distressing diseases with no significant 
cure for several types of tumors [1, 2]. Cancer is principally a disease of 
cells identified by the loss of normal cellular growth, maturation and 
multiplication leading to disturbance of homeostasis. A brief 
consideration of the challenges facing an anti-cancer drug are–at first the 
drug must be able to seek out differences between a transformed cells 
from other healthy cells in the body. Secondly, they should provide 
sufficiently a high dose of toxic agent to kill the cell. Furthermore, it 
successfully cures a patient by eradicating each and every cancer cell [3]. 
However, conventional chemotherapeutic agents have several 
challenges such as low aqueous solubility, poor bio-distribution, 
unfavorable pharmacokinetics, narrow therapeutic index, poor 
membrane permeability, instability, rapid clearance, severe toxicity, and 
the emergence of multidrug resistance phenotypes. 
Although, it has been observed that cancer chemotherapy is one of 
the best approaches to eradicate cancer and the success of 
chemotherapy mainly depends on the selection of optimum carrier 
system. These carriers include nanoparticles, nano tubes, nano rods, 
dendrimers, liposomes, solid lipid nanoparticles, microspheres etc. 
Among all these, dendrimeric system appears to be promising in 
cancer chemotherapy, especially via ligand or Receptor-mediated 
endocytosis as it possess numerous properties [especially surface 
property] to target cancer and also to overcome all these limitations 
of conventional chemotherapeutic agents, there is an immediate 
need for developing safe and effective carrier vectors such as 
dendrimers that can protect the drug from degradation during 
transit and enhance targeting efficiency and also reduce adverse 
toxic effects caused by cytotoxic drugs [2]. 
Dendrimers are highly branched, nanosized, symmetric molecules 
with well defined, homogenous and monodisperse structure having 
diameter in 2-10 nm range. The word Dendrimer is based on the 
Greek words-“Dendron meaning tree or branch” and 
“merosmeaningpart” [3]. The structure of the denrimers is shown in 
fig. 1. The three component of dendrimer are central core, repetitive 
branching units and terminal groups. The “Generation number” of 
dendrimer is determined by the increase in a number of branching 
units which results in globar structure formation [4-7]. Palmerston 
Mendes L, Pan J, Torchilin VP 2017, has inferred in their review 
article that the presence of functional groups in the dendrimer’s 
exterior also permits the addition of other moieties that can actively 
target certain diseases and improve delivery which is now widely 
used as tumor targeting [4]. The presence of unique properties 
makes them ideal carriers for the targeted delivery of therapeutic 
and diagnostic agents [8]. 
 
 
Fig. 1: Structure of dendrimer 
Source-bitspace.com
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Advantages of dendrimers over conventional anti-cancer agents 
 High drug loading capacity 
 Dendrimers having appropriate nanosize ranging 1-100 nm for 
pre detectable release profile, favorable pharmacokinetics and 
targeting potentials [2, 9]. 
 Dendrimer improve the solubility of poorly soluble anti-
neoplastic drugs. 
 Clearance is reduced through Reticuloendothelial system due to 
small size [10-12]. 
 Multiple functional groups are present on outer surface of 
dendrimers, which can be used to attach vector devices for targeting 
to particular site in the body. 
 Presence of numerous peripheral functional groups on 
dendrimers is responsible for tumor cell-specific delivery.  
Toxicity and its management 
 It is known that all classes of dendrimers present cytotoxic and 
hemolytic properties which raise concern according to their safety. 
 The toxicity is dependent on the dendrimer characteristics and 
can be related to the chemistry of the core but mainly to surface end 
groups [4, 13]. 
 Interaction of the cationic dendrimers surfaces with negative 
biological load membranes damaging cellular membranes causing 
hemolytic toxicity and cytotoxicity [14]. 
 This strong interaction with the negatively charged cell 
membranes can cause cell destabilization with leakage of 
cytoplasmic proteins and subsequently lysis [4, 15-16]. 
E. g.: Interaction with lipid bilayers of cells occurs with the cationic 
Dendrimer G7-PAMAM which comes to form holes 15-40 nm in 
diameter, which disturbs the flow of electrolyte causing cell death. 
[14, 17-19] 
 Surface modification of dendrimers can be useful to improve 
their safety and can be easily achieved through conjugation 
molecules with the reactive terminal groups of nanocarriers. 
 PEG is frequently used to increase plasma circulation time and 
tumor accumulation through enhanced permeability and retention 
effect [EPR] [4, 20-22]. 
 Linking or conjugation of dendrimers with PEG chains has been 
shown as an important step in reducing the cytotoxicity of 
dendrimers 
 PEGylation increase the physical dendrimers size which reduces 
renal clearance since the glomerular filtration limits reached [4, 23-
26].
 
Table 1: Anti-cancer drugs delivered by using dendrimers 
S. No. Anti-cancer drugs Dendrimer type 
1 5-FU(5-Flurouracil) PAMAM-mPEG-PDEA 
PAMAM 
Polyglycerol 
2 CDDP(Cisplatin) PAMAM 
PAMAM-COOH 
3 MTX(Methotrexate) Polyether-co-polyester PAMAM 




5 DOX(Doxorubicin) PEGylated-PAMAM 
Poly ester 






Fig. 2: Gerenal representation of the model structure of a dendrimer  
Source: pubmed 
 
Drug delivery as carriers  
Dendrimers act as a carrier for the delivery of anti-cancer drugs by 
either encapsulation of the drug in the interior of the dendrimer or 
conjugating covalently to form macromolecular prodrug [27]. 
Drug encapsulated dendrimers 
• Poly (glycerol-succinic acid) dendrimers were investigated as 
delivery vehicles for camptothecin. In a preliminary study reported 
by the Grinstaff group, G4-PGLSA dendrimers with hydroxyl and 
carboxyl peripheral groups were used to encapsulate 10-hydroxy 
camptothecin for delivery to cancer cells [28]. 
• Melamine–based dendrimers were used to solubilize the anti-
cancer drugs Methotrexate and 6-mercaptopurine, as well as to 
reduce toxicity [29]. 
• A major drawback to these delivery systems is a lack of controlled 
drug release kinetics, with most systems releasing their payload over the 
course of several hours. For this reason, drug encapsulated dendrimer 
systems may best be utilized via direct intratumoral injection. 
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Fig. 3: Encapsulation of various types of drug into dendrimers 
Source: Pubmed 
 
Dendrimer drug conjugates: [27] 
• Dendrimer drug conjugate consists of anti-neoplastic agent 
covalently attached to the peripheral groups of the dendrimer. 
• This method has distinct advantages over drug encapsulated 
systems such as  
1. Multiple drug molecules can be attached to each dendrimer molecule. 
2. Nature of linkages controls the release of therapeutic molecules. 
• Paclitaxel was conjugated to PEG or G4PAMAM to compare the 
anti-cancer activity of the drug delivered by a linear or dendritic 
carrier [30]. Both PEG and PAMAM increased the aqueous solubility 
of paclitaxel (0.3mcg/ml) dramatically to 2.44mcg/ml and3.2 
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Drug delivery by various types of dendrimers 
The utility of dendrimers can be well known by their ability to 
traverse several delivery barriers using two principles, namely 
active and passive tumor targeting. 
 Passive targeting-utilizes EPR effect which involves 
dendrimers to extravasate and accumulates selectively in the tumor 
tissue. 
 Active targeting- It involves conjugation of specific targeting 
ligands on nanocarrier surfaces can facilitate their selective binding 
to overexpressed receptors on specific tumor cells. 
Moreover, a Passive targeting approach (or) the EPR effect is only 
applicable to highly permeable solid tumors. However, the 
permeability of several tumor types is very low or non-uniform 
throughout heterogeneous tumors. These shortcomings can be 
resolved by Active targeting approach only which enables 
conjugation of a variety of cancer targeting ligands. 
1. PAMAM dendrimers (Poly amidoamine) dendrimers 
It is principally used as carriers for anti-cancer therapy. 
e. g.: 
a) Phosphoryl choline-conjugated fifth generation PAMAM 
dendrimers have been developed for the delivery of an anti-cancer 
drug “Adriamycin” [2]. 
b) To improve the drug accumulation in lungs tumor, prepared DOX-
dendrimer conjugates and investigated their ability to decrease 
metastatic lung burden through the administration of these 
Nanosystems [4]. 
4.0 G PAMMAM dendrimers have been conjugated with two targeting 
ligands, namely Transferrin (TF
 
) and wheat germ agglutinin (WGA) 
and utilize d for the purpose of traversing the blood-brain barrier and 
Ingestion of drugs by brain tumor cells. Thus, provide a potential 
application for brain cancer therapy [2, 31]. 
 
Fig. 7: Cellular uptake of drug from dendrimer by passive targeting 
Source: Science direct article Reference No. 2 
 
 
Fig. 8: Cellular uptake of drug from Dendrimer by Active targeting 
Source: Science direct article Reference No. 2 
 
2. PPI Dendrimers (Poly-propylene Imine) dendrimers 
• These are amine terminated hyperbranched macromolecules that 
are mainly synthesized by a divergent method [2, 32]. 
• Amine groups on periphery enable various cancer-targeting 
ligands such as Folates, amino acids, carbohydrates, antibodies, 
peptides that are explored for active targeting. 
E. g.:  
a) G4.5PPI dendrimers that were carboxylic acid terminated to 
conjugate the monoclonal antibody mAbk1 to encapsulate paclitaxel 
(PTX). It targets Mesothelin protein, overexpressed in some cancers 
but not in normal cells [4, 33] 
b) Nanoconjugates of DOX were prepared by coupling with fifth 
generation PPI dendrimers using unique aromatic azo linkers (L1-
L4) that could be selectively recognized and cleaved using 
azoreductase enzymes present in the cytoplasm of hepatic cancer 
cells. Hence, this approach could be successfully explored for 
controlled delivery of drugs to hepatic cancer cells [2, 34]. 
c) Polysorbate-80 conjugated PPI dendrimers were explored for 
targeted delivery of DTX to the brain tumor. 
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3. PLL Dendrimers: (Poly–L-lysine) dendrimer 
PLL dendrimers less well studied than PAMAM or PPI. Also, they 
found to be greatly associated with DOX and improve the drugs anti-
cancer activity while showing fewer adverse events than the free 
drug [44, 21, 35, 36]. 
E. g.: 
a) The hydrophobic cavity of 6.0G PLL dendrimers anchored with 
PEG-linked hydrophobic pentaphenyl alanine are used to deliver 
DOX by I. V. which resulted in tumor accumulation by the EPR effect 
and led to the suppression of tumor growth without loss of body 
weight [2, 37]. 
b) PLLDendrimers of generation 6 had well anti-angiogenic 
activity in an in vivo B16F10 Xenograft model (brain, lung, liver 
cancer) even in absence of therapeutic molecule. By associating 
the PLL dendrimers with DOX they attempted to combine the 
anti-cancer effect of the drug and anti-angiogenic effect of 
carrier [4, 36]. 
 
Table 2: Commonly used dendrimers as drug carriers [4] 
S. No. Polymer Generation Pay load Application 























A glimpse of researches of dendrimers in cancer therapy 
Sylwia Michlewska et al., 2018, stanch to study interactions between 
new carbosilane-based metallodendrimers containing ruthenium 
and anti-cancer small interfering RNA (siRNA). Formation of 
complexes between anti-cancer siRNAs and Ru-based carbosilane 
dendrimers was evaluated by transmission electron microscopy, 
circular dichroism, and fluorescence. The zeta-potential and the size 
of dendriplexes were determined by dynamic light scattering. The 
internalization of dendriplexes was estimated using HL-60 cells. 
Results show that ruthenium dendrimers associated with anticancer 
siRNA have the ability to deliver siRNA as non-viral vectors into the 
cancer cells. Moreover, dendrimers can protect siRNA against 
nuclease degradation [38]. 
Kelly E. Burnsa, James B. Delehanty 2018, had developed a peptide-
dendrimer-drug conjugate system for the pH-triggered direct 
cytosolic delivery of the cancer chemotherapeutic doxorubicin 
(DOX) using the pH Low Insertion Peptide (pHLIP). In their research, 
they synthesized a pHLIP-dendrimer-DOX conjugate in which a 
single copy of pHLIP displayed a generation three dendrimer 
bearing multiple copies of DOX via disulfide linkages. Biophysical 
analysis showed that both the dendrimer and a single DOX conjugate 
inserted into membrane bilayers in a pH-dependent manner. Time-
resolved confocal microscopy indicate the single DOX conjugate may 
undergo a faster rate of membrane translocation, due to the greater 
nuclear localization of DOX at 24 h and 48 h post-delivery. At 72 h, 
however, the levels of DOX nuclear accumulation for both constructs 
were identical. Cytotoxicity assays revealed that both constructs 
mediated ∼80% inhibition of cellular proliferation at 10 µM, the 
dendrimer complex exhibited a 17%greater cytotoxic effect at lower 
concentrations and greater than three-fold improvement in IC50 
over free DOX. Their findings show proof of concept that the 
dendrimeric display of DOX on the pHLIP carrier (1) facilitates the 
pH-dependent and temporally-controlled release of DOX to the 
cytosol, (2) eliminates the endosomal sequestration of the drug 
cargo, and (3) augments DOX cytotoxicity relative to the free drug 
[39]. 
Jun Cao et al., 2018, has used small nanoparticles as a potentiator of 
conventional chemotherapy by co-administration with free 
chemotherapeutic agents. Their strategy avoided the problems 
associated with drug loading and controlled release encountered in 
NDDS, and was also much simpler than NDDS. Negatively charged 
poly (amidoamine)-2,3-dimethylmaleic monoamide (PAMAM-DMA) 
dendrimers were prepared, which possessed low toxicity and can be 
converted to positively charged PAMAM dendrimers responsive to 
tumor acidic pH. The in situ formed PAMAM in tumor tissue 
promoted cellular uptake of co-administered doxorubicin by 
increasing the cell membrane permeability and subsequently 
enhanced the cytotoxicity of doxorubicin. The small size of the 
dendrimers was found to be favorable for deep penetration in 
tumor. Co-injection of PAMAM-DMA with doxorubicin into nude 
mice bearing human tumors almost completely inhibited tumor 
growth, with a mean tumor weight reducing by 55.9% after the 
treatment compared with the treatment with doxorubicin [40]. 
Kuruvilla SP et al., 2018, were interested to see if tri-valent NAcGal 
ligands (i.e. NAcGal3) displayed on G5 dendrimers (i.e. G5-cPEG-
NAcGal3; tri Gal) could improve their ability to target hepatic cancer 
cells compared to their mono Gal counterparts. They, therefore, 
synthesized a library of tri Gal particles, with either 2, 4, 6, 8, 11, or 
14 targeting branches (i.e. cPEG-NAcGal3) attached. Conventional 
flow cytometry studies showed that all particle formulations can 
label hepatic cancer cells in a concentration-dependent manner, 
reaching 90-100% of cells labeled at either 285 or 570 nM G5, but 
interestingly, monoGal labeled more cells at lower concentrations. 
To elucidate the difference in internalization of monoGal versus 
triGal conjugates, we turned to multi-spectral imaging flow 
cytometry and quantified the amount of internalized (I) versus 
surface-bound (I0) conjugates to determine the ratio of 
internalization (I/I0) in all treatment groups. Results show that 
regardless of NAcGalvalency, or the density of targeting branches, all 
particles achieve full internalization and diffuse localization 
throughout the cell (I/I0  ∼ 3.0 for all particle compositions). This 
indicates that while tri-valentNAcGal is a promising technique for 
targeting nanoparticles to hepatic cancer cells, mono-valentNAcGal 
is more efficient, contrary to what is observed with small molecules 
[41]. 
Narsireddy Amreddy et al., 2018, Co-administered functionally 
distinct anti-cancer agents as an efficient strategy in lung cancer 
treatment. The study reported that they required aes a specially 
designed drug delivery system to co-encapsulate functionally 
different agents, such as a combination of siRNA and chemotherapy, 
for targeted delivery. Hence they developed a folic acid (FA)–
conjugated polyamidoamine dendrimer (Den)-based nanoparticle 
(NP) system for co-delivery of siRNA against HuR mRNA 
(HuRsiRNA) and cis-diamine platinum (CDDP) to folate receptor-α 
(FRA)–overexpressing H1299 lung cancer cells. The co-delivery of 
HuRsiRNA and CDDP using theFRA-targeted NP had a significantly 
greater therapeutic effect than did individual therapeutics. Further, 
the FRA-targeted NP exhibited improved cytotoxicity compared to 
non-targeted NPagainst lung cancer cells. Finally, the NP showed 
negligible toxicity towards normal MRC9 lung fibroblast cells [42].  
Chuda Chittasupho et al., 2017, hypothesized that targeted inhibition 
of CXCR4 in breast cancer cells should suppress CXCR4-positive 
tumor cells toward secondary metastatic sites. They emphasized 
their research to identify the efficacy of CXCR4 targeted dendrimers 
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carrying DOX (LFC131-DOX-D4) on cellular binding, cytotoxicity and 
migration of BT-549-Luc and T47D breast cancer cells was 
investigated. PAMAM dendrimers encapsulating DOX was surface 
functionalized with LFC131 peptide which recognized CXCR4 
expressed on the surface of breast cancer cells. The LFC131-DOX-D4 
bound to breast cancer cells resulting in significantly enhanced in 
vitro cellular toxicity as compared with non-targeted dendrimers. 
The LFC131-D4 exhibited remarkable reduced migration of BT-549-
Luc breast cancer cells toward chemoattractant. Finally, the work 
demonstrated the potential utility of LFC131-dendrimer conjugates 
for breast cancer therapy and metastasis [43]. 
Nigam S, Bahadur Det al., 2017, demonstrates the fabrication and 
characterization of a new class of cationic, biocompatible, peptide 
dendrimers, which were then used for stabilizing and 
functionalizing magnetite nanoparticles for combinatorial therapy of 
cancer. The synthesized peptide dendrimers have the edge over the 
widely used PAMAM dendrimers due to better biocompatibility and 
negligible cytotoxicity of their degradation products. The surface 
engineering efficacy of the peptide dendrimers and their potential 
use as drug carriers were compared with their PAMAM 
counterparts. The peptide dendrimer was found to be as efficient as 
PAMAM dendrimers in its drug-carrying capacity, while its drug 
release profiles substantially exceeded those of PAMAM's. A dose-
dependent study was carried out to assess their half maximal 
inhibitory concentration (IC50) in vitro with various cancer cell 
lines. A cervical cancer cell line that was incubated with these 
dendritic nanoparticles was exposed to the alternating current 
magnetic field (ACMF) to investigate the effect of elevated 
temperatures on the live cell population. The DOX-loaded 
formulations, in combination with the ACMF, were also assessed for 
their synergistic effects on the cancer cells for combinatorial 
therapy. The results established the peptide dendrimer as an 
efficient alternative to PAMAM, which can be used successfully in 
biomedical applications [44]. 
Ozturk Ket al., 2017, developed a dendrimer-based drug delivery 
system targeting Flt-1 (a receptor for vascular endothelial growth 
factors (VEGF)) receptor to improve the therapeutic efficacy of 
gemcitabine in pancreatic cancer. Synthesized polyethylene glycol 
(PEG)-cored PAMAM dendrimers, which bear anionic carboxylic acid 
groups on the surface were modified with PEG chains, which were 
then conjugated with Flt-1 antibody. Following structural and 
chemical characterization studies, gemcitabine HCl-dendrimer 
inclusion complexes were successfully prepared. These complexes 
were efficiently engulfed by Flt-1 expressing pancreatic cancer cells, 
which enhanced the cytotoxicity of gemcitabine. Moreover, 
pancreatic tumors established in mice were highly targeted by PEG-
cored Flt-1 antibody-conjugated dendrimers and increased 
accumulation of these gemcitabine-loaded complexes exhibited 
satisfactory in vivo anti-cancer efficacy [45].  
Bodewein L et al., 2016, has tested polyamidoamine (PAMAM) 
dendrimers of generations G3.0, 3.5, 4.0, 4.5 and 5.0 and 
polypropylenimine (PPI) dendrimers G3.0, 4.0 and 5.0 in zebrafish 
embryos for 96h and human cancer cell lines for 24h, to assess and 
compare developmental in vivo toxicity with cytotoxicity. The 
zebrafish embryo toxicity of cationic PAMAM and PPI dendrimers 
increased over time, with EC50 values ranging from 0.16 to just 
below 1.7μM at 24 and 48hpf. The predominant effects were 
mortality, plus reduced heartbeat and blood circulation for PPI 
dendrimers. Apoptosis in the embryos increased in line with the 
general toxicity concentration-dependently. Hatch and 
dechorionation of the embryos increased the toxicity, suggesting a 
protective role of the chorion. Lower generation dendrimers were 
more toxic in the embryos whereas the toxicity in the HepG2 and 
DU145 cell lines increased with increasing generation of cationic 
PAMAMs and PPI dendrimers. HepG2 were less sensitive than 
DU145 cells, with IC50 values≥402μM (PAMAMs) and ≤240μM 
(PPIs) for HepG2 and ≤13.24μM (PAMAMs) and ≤12.84μM (PPIs) for 
DU145. Neither in fish embryos nor cells toxicity thresholds was 
determinable for anionic PAMAM G3.5 and G4.5. Their study 
demonstrated that the cytotoxicity underestimated the in vivo 
toxicity of the dendrimers in the fish embryos [46]. 
Prashant Kesharwani et al., 2014, describes comparative data 
pertaining to generation dependent cancer targeting propensity of 
Poly (-propyleneimine) (PPI) dendrimers. PPI dendrimers of 
different generations (3.0G, 4.0G and 5.0G) were synthesized and 
loaded with Melphalan. Results from loading, hemolysis, 
hematologic, cytotoxicity and flow cytometry assay depicted that as 
the generation of dendrimer increased from fourth to fifth, the only 
parameter i.e. toxicty is increased exponentially. However, others 
parameters, i.e. loading, sustained release behavior, and targeting 
efficacy increased negligibly. Kaplan-Meier survival curves clearly 
depicted comparable therapeutic potential of PPI4M with PPI5M. In 
vivo investigations in Balb/c miceagain favored 4.0G PPI dendrimer 
to be preferable nanocarrier for anticancer drug delivery owing to 
analogous anticancer potential. The outcomes of the investigation 
evidently projects 4.0G PPI dendrimerover 3.0G and 5.0G dendrimer 
in respect of its drug delivery benefit as well as superior 
biocompatibility [47]. 
Wenjun Yang et al., 2009, executed their research by conjugating 
partially acetylated generation 5 (G5) polyamidoamine(PAMAM) 
dendrimer with the targeting moiety (biotin) and the imaging 
moiety (fluorescein isothiocyanate, FITC), and the resulting 
dendrimer-biotin conjugate was characterized by 1
Advances in nanotechnology have enabled development of 
dendrimers that can be used as diagnostic aids in diverse molecular 
imaging application, particularly diagnostic applications such as- 
H NMR, UV-vis 
spectrum. As revealed by flow cytometry and confocal microscopy, 
the bifunctional conjugate (dendrimerebiotineFITC) exhibited much 
higher cellular uptake into HeLa cells than the conjugate without 
biotin. The uptake was energy-dependent, dose-dependent, and 
could be effectively blocked by dendrimer-conjugated biotin. Their 
results indicated that the biocompatible biotinedendrimer conjugate 
might be a promising nano-platform for cancer therapy and cancer 
diagnosis [48]. 
Diagnostic applications of dendrimers 
 
 
Fig. 9: Nanodevices as a link between detection, diagnosis and treatment 
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a. Cancer Imaging 
b. Photodynamic therapy 
c. Boron neutron capture therapy 
d. Tecto-dendrimer Nanodevice 
e. Photothermal therapy  
a. Cancer imaging 
 Imaging techniques are used in cancer therapy to diagnose and 
identify the location of the disease sites, stage, plan treatment and 
potentially find recurrence. 
 MRI is a non-invasive technique for the diagnosing tumors in soft 
tissues [8]. 
 MRI agents were linked with dendrimer molecules for contrast 
enhancement, improved clearance characteristics and potential 
targeting. 
E. g.: Gadolinium contrast agents have been conjugated to PPI 
and evaluated for use as macromolecular MR contrast agents 
[27, 49]. 
 Computer tomography is a standard method of imaging 
associated with cancer diagnosis. 
 Similar to Gd-Dendrimer for MRI, Iodinated contrast agents used for 
CT. 
E. g.: Synthesis of iodinated contrast agents based on 
Iobitridolconjugated G3-G5 poly (lysine) dendrimers with PEG cores 
of varying lengths for possible tumor microvasculature CT-Imaging 
[27, 50]. 
b. Photodynamic therapy: (PDT) 
 Photodynamic therapy relies on the activation of a 
photosensitizing agent with visible or near IR light [27]. 
 When photosensitizer exposed to specific wavelength of light, 
they produce form of oxygen which kills cancer cells [51, 52]. 
 PDT has been shown to reduce tumors by direct cell killing, 
destruction of tumor neovasculature and triggering of an acute 
inflammatory response that attracts leukocytes to the tumor 
[27]. 
 Dendrimers in PDT are designed to-[51,52] 
• Deliver the agent only to affected tissues by recognizing the 
specific molecule on cancer cell. 
• Fasten the rate of treatment. 
• No need to wait for elimination of photosensitizer from normal cells. 
c. Boron neutron capture therapy-(BNCT) 
 BNCT is based on a lethal [10]B(n,α)7 
 The emergence of BNCT as a significant clinical treatment has 
been limited by either lack of sufficient tumor targeting or sub-
therapeutic [10] baccumulationin malignant tissues. 
Li capture reaction that 
occurs [10]B is irradiated with low energy thermal neutrons to 
produce high energy α-particles and 7 Li nuclei  
 To this end macromolecular delivery vehicles have been prepared 
to enhance both the quantity of and targeting of [10]B to tumor cells 
by conjugating Boron containing complexes to monoclonal 
antibodies or receptor targeting agents [27, 52]. 
 Boron present adjacent to the tumor cells disintegrates after 
capturing neutrons produce high energy heavy charged particles 
that destroy only cells in close proximity to it leaving adjacent 
normal cells [51,52] 
E. g.: Dendrimers like PAMAM-transfer 5000 Boron derivatives. 
d. Tectodendrimer as nanodevice [51] 
Tecto dendrimers are multifunctional devices built from a core 
dendrimer, surrounded by shell dendrimers. Each shell dendrimer 
performs one function  
e. Photothermal therapy [27] 
 Gold-based nanoparticles have been developed that strongly 
absorb light in the near IR region, facilitating deep optical 
penetration into tissues, generating a localized lethal dose of heat at 
the site of the tumor. 
 Dendrimer-encapsulated gold nanoparticles have been prepared 
and identified for their potential use towards the photothermal 
treatment of malignant tissue. 
E. g. Amine-terminated G5-PAMAM dendrimer-entrapped gold 
nanoparticles were prepared and covalently conjugated to 
fluorescein and folic acid for targeted delivery to tumor cell 
overexpressing folic acid receptors. 
CONCLUSION 
Nowadays understanding the disease, development of newer 
targeted therapies and treatment of several forms of cancer remains 
a major challenge. Among all the latest developed Nanotechnologies, 
Dendrimer mediated drug delivery has emerged as a superior 
opinion to overcome the shortcomings of conventional 
chemotherapy. Dendrimer act as a carrier for the delivery of drug to 
tumor by encapsulation (or) conjugation. This delivery to tumor site 
mostly occurs through PAMAM, PPI, and PLL dendrimers by either 
passive or active targeting. Many advances have been made to 
obtain safe and efficacious dendrimer-based formulation for 
increasing the specificity and efficacy towards diagnosis and 
treatment of cancer. The future scope of dendrimers in research 
depends on its applicability in areas such as synthesis, drug delivery, 
biotechnology, nanotechnology, detection, catalyst and cosmetics. 
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